The authors of an accompanying editorial discuss how these findings should be interpreted into clinical practice, as vincristine remains a component of the most widely accepted treatment regimens for childhood ALL. They say that it is unclear whether vincristine can be removed from the treatment options for a child with CEP72 variants, although the findings suggest vincristine dose reductions may be possible without compromising efficacy. It is unclear if CEP72 variants also are associated with vincristine-related peripheral neuropathy in treatment of adult ALL, lymphomas, and solid tumours.